Intelligence · Patents
Patents expiring in 2034
Annual patent cliff calendar for 2034 — US pharmaceutical patents by expiration date.
- Patents
- 1,452
Quick answer
1,452 indexed pharmaceutical patents have expiration dates in 2034. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8846648
Natural combination hormone replacement formulations and therapies
granted -
US 8846866
Aldehyde tags, uses thereof in site-specific protein modification
granted -
US 8846908
Tricyclic carbamate JAK inhibitors
granted -
US 8846859
Compositions and methods of use of targeting peptides against placenta and adipose tissues
granted -
US 8846770
Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
granted -
US 8846752
Isoflavone fatty acid ester derivatives, preparation method and pharmaceutical uses thereof
granted -
US 8846918
Compounds useful as inhibitors of ATR kinase
granted -
US 8846684
Arbovirus inhibitors and uses thereof
granted -
US 8846686
Compounds useful as inhibitors of ATR kinase
granted -
US 8846718
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
granted -
US 8853254
Modulators of ATP-binding cassette transporters
granted -
US 8853325
Water-soluble polymer alkanals
granted -
US 8852447
Porous nanostructures and methods involving the same
granted -
US 8852568
Compositions and methods for treating and preventing skeletal muscle deficiencies
granted -
US 8852576
Modified sodium iodide symporter proteins and uses thereof
granted -
US 8852598
Puumala virus full-length M segment-based DNA vaccines
granted -
US 8852151
Swallowable drug delivery device and method of delivery
granted -
US 8852940
Embryonic stem cell specific microRNAs promote induced pluripotency
granted -
US 8853152
Pharmaceutical compositions
granted -
US 8853151
Pro-drug complexes and related methods of use
granted -
US 8852626
Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
granted -
US 8852936
Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
granted -
US 8853160
GLP-1, exendin-4, peptide analogs and uses thereof
granted -
US 8853205
Heteropyrrole analogs acting on cannabinoid receptors
granted -
US 8853217
Compounds useful as inhibitors of ATR kinase
granted -
US 8853228
Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase
granted -
US 8853244
Thiophene-carboxamides useful as inhibitors of protein kinases
granted -
US 8853255
3-phenoxymethylpyrrolidine compounds
granted -
US 8853271
Method for inhibiting activity and/or expression of matrix metalloproteinase, inhibiting phosphorylation of mitogen-activated protein kinase, and/or promoting expression of collagen using tormentic acid
granted -
US 8853252
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
granted -
US 8853277
Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)
granted -
US 8853356
Use of pentagastrin to inhibit gastric acid secretion or as a diuretic
granted -
US 8852605
Vibrio cholerae O139 conjugate vaccines
granted -
US 8853215
Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes
granted -
US 8853415
Modulators of ATP-binding cassette transporters
granted -
US 8853247
Oligomer-nitroimidazole anti-infective conjugates
granted -
US 8853427
Neprilysin inhibitors
granted -
US 8853397
2,4-pyrimidinediamine compounds and their uses
granted -
CA 2908706
TRAITEMENTS UTILISANT L'ESLICARBAZEPINE ET L'ACETATE D'ESLICARBAZEPINE
granted -
WO 2014163518
TRAITEMENTS UTILISANT L'ESLICARBAZÉPINE ET L'ACÉTATE D'ESLICARBAZÉPINE
granted -
CA 2905273
RENFORCATEURS D'HYDROSOLUBILITE A BASE DE GLYCOGENE
granted -
US 8859520
Methods for therapy of neurodegenerative disease of the brain
granted -
US 8859585
Scopolamine for the treatment of depression and anxiety
granted -
US 8859498
Targeted therapeutic proteins
granted -
US 8859716
Degradable thiol-ene polymers
granted -
US 8859512
Anti-viral pyrimidine nucleoside derivatives
granted -
US 8859506
Glycopeptide phosphonate derivatives
granted -
US 8859499
Method of enhancing efficacy of blood transfusions
granted
Frequently asked questions
How many pharma patents expire in 2034?
1,452 published patents in our USPTO index have expiration dates falling in calendar year 2034.